SCHEMBL1249596

SCHEMBL1249596

CCCc1ccc(-c2ccc3cc(OCC)c(F)c(F)c3c2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 2/20 0.39
FGFR1 P11362 1/20 0.39
MPL P40238 4/20 0.37
FFAR4 Q5NUL3 2/20 0.37
GABRA1 P14867 4/20 0.37
GABRB2 P47870 4/20 0.37
S1PR1 P21453 3/20 0.36
S1PR3 Q99500 3/20 0.36
RARB P10826 1/20 0.36
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17997295 0.86 FFAR4 (0.39) FGFR2FGFR1MPLFFAR4GABRA1
SCHEMBL13026125 0.83 GABRA1 (0.35) FGFR2FGFR1GABRA1GABRB2S1PR1
SCHEMBL21609905 0.83 GABRA1 (0.41) FGFR2FGFR1MPLFFAR4GABRA1
SCHEMBL1249598 0.82 MPL (0.39) MPLFFAR4RARBHSD17B10NPC1
SCHEMBL3437380 0.82 GABRA1 (0.42) FGFR2FGFR1MPLFFAR4GABRA1
SCHEMBL29873595 0.82 GABRA1 (0.42) FGFR2FGFR1MPLFFAR4GABRA1
SCHEMBL17532035 0.81 RARB (0.33) MPLRARB
SCHEMBL1249490 0.81 MPL (0.43) MPLGABRA1GABRB2RARBALOX5
SCHEMBL9563716 0.80 GABRA1 (0.41) FGFR2FGFR1MPLFFAR4GABRA1
SCHEMBL17946123 0.80 GABRA1 (0.41) FGFR2FGFR1MPLFFAR4GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1544187-B1 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHODS FOR PRODUCING LIQUID CRYSTAL COMPOUNDS USING SAME DAINIPPON INK & CHEMICALS (JP) 2011-02-16 EP disclosed
US-7214835-B2 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same DAINIPPON INK & CHEMICALS, INC. (JP) 2007-05-08 US disclosed
US-7214835-B2 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same DAINIPPON INK & CHEMICALS, INC. (JP) 2007-05-08 US disclosed
US-20060163537-A1 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-07-27 US disclosed
EP-1544187-A1 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHOD FOR PRODUCING LIQUID CRYSTAL COMPOUND USING SAME DAINIPPON INK AND CHEMICALS, INC. (JP) 2005-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060163537-A1 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same NOC2L, SNX2, NEFM FGFR2 275/4885FGFR1 179/4885MPL 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.